Cellzome is a world leader in chemoproteomics, transforming the sciences of epigenetics and signal transduction into novel drug candidates in inflammatory diseases and oncology.
The Company maintains the highest levels of scientific expertise and has active collaborations with the foremost academic laboratories around the world.
Cellzome's technologies work with native proteins in a physiological setting to discover small molecule drugs targeting protein complexes that underlie diseases.
The Company has a track record in delivering significant collaborations with top pharmaceutical companies including GlaxoSmithKline, Johnson & Johnson and Novartis.
The management team has strong scientific and commercial credentials, and is backed by some of the biotech industry's most experienced investors.
Cellzome is a privately-held, international, company located in Heidelberg, Germany and Cambridge, UK employing about 100 people.